Xin Lang Cai Jing·2026-01-10 00:48Group 1 - Merck is in negotiations to acquire cancer drug developer Revolution Medicines for a price between $28 billion and $32 billion, with the deal potentially being the largest in the pharmaceutical industry in three years [3][4] - Following the news, Revolution Medicines' stock surged nearly 16% in after-hours trading, indicating strong market interest in the potential acquisition [3] - Other major pharmaceutical companies are also monitoring Revolution Medicines, suggesting the possibility of competing bids, which adds uncertainty to the outcome of the negotiations [3] Group 2 - If the acquisition is successful, Merck is expected to gain access to the experimental drug Daraxonrasib, which is in late-stage clinical trials and has received FDA fast track designation [4] - Daraxonrasib targets various mutations of the RAS gene, which are common drivers of several cancers, including pancreatic, lung, and colorectal cancers [4] - Analysts from Mizuho Securities project that the global risk-adjusted sales of Revolution Medicines' RAS inhibitor portfolio could exceed $10 billion by 2035 [4]